1. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation.
- Author
-
de Alboran IM, O'Hagan RC, Gärtner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, and Alt FW
- Subjects
- Animals, B-Lymphocytes cytology, B-Lymphocytes drug effects, B-Lymphocytes metabolism, B-Lymphocytes physiology, CD40 Antigens immunology, Cell Cycle, Cells, Cultured, Cyclin-Dependent Kinase Inhibitor p27, Cyclin-Dependent Kinases antagonists & inhibitors, Fibroblasts cytology, Fibroblasts metabolism, G1 Phase, Gene Targeting, Interleukin-4 immunology, Interleukin-4 pharmacology, Lymphocyte Activation, Mice, Mice, Inbred C57BL, Microtubule-Associated Proteins metabolism, Mitogens immunology, Mitogens pharmacology, Mutation, Proto-Oncogene Proteins c-myc genetics, Proto-Oncogene Proteins c-myc metabolism, Resting Phase, Cell Cycle, Cell Cycle Proteins, Proto-Oncogene Proteins c-myc physiology, Tumor Suppressor Proteins
- Abstract
Germline inactivation of c-myc in mice causes embryonic lethality. Therefore, we developed a LoxP/Cre-based conditional mutation approach to test the role of c-myc in mouse embryonic fibroblasts (MEFs) and mature B lymphocytes. Cre expression resulted in reduced proliferation of wild-type MEFs, but c-Myc-deficient MEFs showed a further reduction. In contrast to fibroblasts, Cre expression had no apparent affect on wild-type B cell proliferation. Deletion of both c-Myc genes in B cells led to severely impaired proliferation in response to anti-CD40 plus IL-4. However, treated cells did upregulate several early activation markers but not CD95 or CD95 ligand. We discuss these findings with respect to potential c-Myc functions in proliferation and apoptosis and also discuss potential limitations in the Cre-mediated gene inactivation approach.
- Published
- 2001
- Full Text
- View/download PDF